Clinical Trial Update: Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) [Phase 2]

View source ↗

Summary

A Phase 2 trial (MK-5592-127) is evaluating intravenous and oral posaconazole in children under 2 years with invasive fungal infection, and the study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Fungal Infection

Drugs mentioned

• POSACONAZOLE (POSACONAZOLE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Invasive Fungal Infection | Phase 2 | Status: RECRUITING